Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.

@article{Zemanov2008LowdoseTR,
  title={Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.},
  author={Mark{\'e}ta Zemanov{\'a} and Vlastimil {\vS}{\vc}udla and Z Weber Adam and Ev{\vz}en Gregora and Luděk Pour and Jiri Minarik and Petr Pavl{\'i}{\vc}ek and Tom{\'a}{\vs} Pika and Jaroslav Ba{\vc}ovsk{\'y}},
  journal={Neoplasma},
  year={2008},
  volume={55 4},
  pages={
          345-9
        }
}
Thalidomide has been estimated as a useful drug in therapy of refractory or relapsed multiple myeloma. Recently, several studies have shown very good results in therapy combination of thalidomide, cyclophosphamide and dexamethasone, but still high doses of thalidomide associated with serious adverse events have been used. In our study, we performed low-dose thalidomide regimens; the aim of this study was to verify the effect and to assess their toxicity. For younger patients up to 65 years we… CONTINUE READING